ACH vs NTRA

Accendra Health Inc.

Aluminum Corporation of China Limited, together with its subsidiaries, manufactures and sells alumina, primary aluminum, and energy products in the People's Republic of China. The company operates through Alumina, Primary Aluminum, Trading, and Energy segments. The Alumina segment mines for and purchases bauxite and other raw materials; and produces and sells alumina, as well as refined alumina. The Primary Aluminum segment procures alumina and other raw materials, supplemental materials, and electrical power; and produces and sells aluminum and aluminum-related products, such as carbon, aluminum alloy, and other electrolytic aluminum products. The Trading segment trades in alumina, primary aluminum, aluminum fabrication products, other non-ferrous metal products, coal products, raw and supplemental materials; and provides logistics and transport services to external customers. The Energy segment engages in coal mining; and generates and sells electricity using thermal power, wind power, and solar power sources to regional power grid corporations, as well as manufactures power related equipment. The company also acquires, manufactures, and distributes bauxite mines and limestone ore; and provides engineering project management, and research and development services. Aluminum Corporation of China Limited was incorporated in 2001 and is headquartered in Beijing, the People's Republic of China.

Natera Inc.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.